-
What a week! Bio-Link was delighted to represent our client,
@ActinogenMed, at#JPM2020. We travelled over 31 km (generally on foot) around San Francisco, meeting with leading pharma executives, sharing the latest exciting data and future strategy for the development of#Xanamem pic.twitter.com/FZYOXZ2777
-
We are delighted to be at
#JPMWeek. This is a great opportunity to update on latest#Xanamem developments. Xanamem has been demonstrated to be an efficacious, brain penetrant & appropriately safe oral drug, with clinical results in line with its intended mechanism of action. pic.twitter.com/DwTYK2E2N7
-
#SACHS_NIF &#JPM2020 Week provides#Actinogen with an excellent opportunity to update the pharmaceutical industry & major global investors interested in Neuroscience on the compelling results achieved with XanaHES, & the expanded#Xanamem dataset generated during 2019.$ACWpic.twitter.com/2qDxWyMRNb
-
Did you miss our presentation at
#AusMicrocap? Will Canty at@boardroom_media speaks to@billketelbey to get an update on#Actinogen, the recent breakthrough results from the XanaHES trial and the exciting pathway forward#xanamem#ASX#investor$ACW http://bit.ly/2N28Ay3 -
@billketelbey is delighted to be presenting at@program_bridge providing his insight on The#Xanamem Journey$ACW#bridgeProgram19https://twitter.com/program_bridge/status/1188656984284729344 …
-
Our 30 Sep 2019 quarter was particularly productive and Actinogen is delighted with the positive XanaHES results released earlier this month
$ACW#Actinogen#investor#biotech#Xanamem@billketelbey https://actinogen.com.au/wp-content/uploads/2019/10/20191024-ASX-1988762-September-2019-Quarterly-Update.pdf … -
$ACW has got to be the best stock of the week so far & maybe month unless another run happens. It went up 466.67% then dropped next day & its back up again today 23.68% The power of#Xanamem#dementia#Alzheimers#Pharmaceutical#ASX#clinicaltrials#clinicalresearch#biotechpic.twitter.com/TMIJgBnXFq
-
Comprehensive suite of studies underway to optimise the future development strategy for
#xanamem https://twitter.com/ActinogenMed/status/1143689349759811584 …
-
Interesting article. Could Actinogen Medical be developing
#xanamem as the next#alzheimersdisease therapy to show benefits for patients?#biotechnology#drugdiscovery#drugdevelopmenthttps://lnkd.in/fRBd7xU -
Actinogen Medical CEO Bill Ketelbey highlighting the great progress and opportunities for
#xanamem!#alzheimersdisease#biotechnology https://lnkd.in/fFyCsuQ -
Congratulations @actinogenmedical - Further support for the safety of
#xanamem in the treatment of#alzheimersdisease https://lnkd.in/fH8V3FF -
.
@ActinogenMed has completed the recruitment of participants for its Phase II clinical trial of#Xanamem for#Alzheimer’s disease. Results are expected in Q2 2019. https://bit.ly/2EdWvlk pic.twitter.com/5rS3ZdnxUR
-
Find out more on XanADu,
#Xanamem and#cortisol in#Alzheimers and other neurological diseases, with commentary from@BillKetelbey and the Xanamem Clinical Advisory Board. https://youtu.be/ckfPGhtNX94 via@YouTube -
“Enrolment of the final patient into XanADu, Ph II
#clinicaltrial of#Xanamem in#Alzheimers, represents a major milestone for#Actinogen, as we now have certainty on the timeline to completion of the trial and reporting out of the results.”@Billketelbeyhttps://www.businesswire.com/news/home/20181125005155/en/Final-Patient-Enrolled-Landmark-Alzheimer%E2%80%99s-Treatment-Trial … -
A significant milestone achieved,
#Actinogen has enrolled final patient into XanADu, its Ph II#clinicaltrials of#Xanamem in the treatment of patients with mild#Alzheimers. Actinogen is on track to report out the results during 2Q CY19. http://bit.ly/2SbtMRN#investor$ACW -
A great day so far at
#AusBioInv!@billketelbey has just given a great presentation regarding@ActinogenMed and#Xanamem https://twitter.com/BioLinkAus/status/1057017274320580610 …
-
RT
@ActinogenMed: September is World Alzheimer's & Dementia Awareness Month. Read more to find out why Actinogen's progress is good news for Alzheimer's patients.@billketelbey#Xanamem#WAM2018#dementia2018#investorhttps://stockhead.com.au/special-report/why-actinogens-progress-is-good-news-for-alzheimers-patients-and-investors/ … -
@billketelbey speaks with Alan Kohler about#Actinogen Medical$ACW and#Xanamem, the novel treatment under development for treating Alzheimer’s Disease. A compelling investment oppprtunity https://theconstantinvestor.com/a-biotech-all-about-alzheimers/ … -
Actinogen Medical continues to make great progress with the development of
#Xanamem for the treatment of#Alzheimers disease. To learn more about this partnering opportunity go to: https://lnkd.in/fkKW78P -
The momentum of XanADu continues to build!
#Xanamem#alzheimers treatment. Learn more about partnering to develop and commercialise Xanamem@BioLinkAushttps://twitter.com/actinogenmed/status/1017197313696022528 …
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.